Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
8
×
san diego blog main
san diego top stories
clinical trials
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
bristol-myers squibb
drugs
fda
intercept pharmaceuticals
new york
nonalcoholic steatohepatitis
abbvie
akcea therapeutics
avexis
cancer
cancer immunotherapy
celgene
What
disease
8
×
drug
approved
fda
liver
nash
roundup
akcea
bio
fatty
help
known
medicine
new
news
patients
race
treatment
according
acorda
advanced
ago
alnylam
alnylam’s
alzheimer's
american
amyloidosis
approval
ash
attr
available
bad
battle
bff
big
biotech
blood
brain
cancer
case
Language
unset
Current search:
disease
×
photo
×
" new york top stories "
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On